D.E. Shaw & Co
BEAM icon

D.E. Shaw & Co’s Beam Therapeutics BEAM Stock Holding History

D.E. Shaw & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55,900
Closed -$1.36M – 4596
2025
Q3 		$1.36M Buy
+55,900
New +$1.11M ﹤0.01% 3253
2022
Q4 		– Sell
-30,000
Closed -$1.43M – 4862
2022
Q3 		$1.43M Buy
+30,000
New +$1.71M ﹤0.01% 3301
2021
Q4 		– Sell
-10,000
Closed -$870K – 5402
2021
Q3 		$870K Hold
10,000
– – ﹤0.01% 3716
2021
Q2 		$1.29M Buy
+10,000
New +$797K ﹤0.01% 3343

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

D.E. Shaw & Co's BEAM Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 27,935 shares — an estimated $774K sold.

D.E. Shaw & Co first reported a position in BEAM in Q1 2021 and held it in 6 quarters. The position peaked at $5.16M in Q3 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 27,935 Beam Therapeutics shares in Q1 2026, an estimated $774K.
  • D.E. Shaw & Co first reported a position in Beam Therapeutics in Q1 2021 and held it in 6 quarters.
  • D.E. Shaw & Co's Beam Therapeutics position peaked at $5.16M in Q3 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.